微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志

• 论文 • 上一篇    下一篇

奥沙利铂联合长春瑞滨或吉西他滨治疗对顺铂和紫杉类耐药或抗拒的晚期非小细胞肺癌

康马飞;骆梅青;李碧慧;涂江江;董翠梅;   

  1. 桂林医学院附属医院肿瘤内科;
  • 收稿日期:2009-12-25 修回日期:2009-12-25 出版日期:2009-12-25 发布日期:2009-12-25

Efficacy of Oxaliplatin combined with Vinorelbine or Gemcitabine on Cisplatin-and Taxane-resistant or refractory advanced non-small cell lung cancer

KANG Ma-fei,LUO Mei-qing,LI Bi-hui,et al.   

  1. (Oncology Department,Affiliated Hospital of Guilin Medical College,Guangxi 541001,China
  • Received:2009-12-25 Revised:2009-12-25 Online:2009-12-25 Published:2009-12-25

赞

被引次数

3

摘要： 目的观察奥沙利铂(OXA)联合长春瑞滨(NVB)或吉西他滨(GEM)治疗对顺铂(DDP)和紫杉醇(PTX)或多西紫杉醇(DOC)抗拒或耐药的晚期非小细胞肺癌(NSCLC)的疗效。方法选择对DDP和PTX或DOC抗拒或耐药的晚期NSCLC60例,随机分为NO组(NVB+OXA)和GEMOX组(GEM+OXA),给予NVB25mg/m2,或GEM1000mg/m2,第1、8天;OXA100mg/m2,第1天,经静脉滴入,每3周重复。结果NO组PR5例,SD13例,PD12例,总有效率(ORR)为16.7%,疾病控制率(DCR)60.0%,肿瘤进展时间(TTP)3.3个月;GEMOX组PR6例,SD11例,PD13例,ORR为20.0%,DCR56.7%,TTP3.4个月。两组比较差异无统计学意义(P>0.05);两组不良反应主要是中性粒细胞减少和外周感觉神经异常,两组差异无统计学意义(P>0.05)。结论OXA联合NVB或GEM治疗对DDP和PTX或DOC抗拒或耐药的晚期NSCLC有效。

关键词: 肺肿瘤, 化学疗法, 奥沙利铂, 长春瑞滨, 吉西他滨, 紫杉醇, 多西紫杉醇

Abstract: Objective To observe the efficacy of Oxaliplatin (OXA) combined with Vinorelbine (NVB) or Gemcitabine (GEM) on Cisplatin (DDP) plus Paclitaxel (PTX) or Docetaxel (DOC) resistant or refractory advanced non-small cell lung cancer (NSCLC).Methods Sixty patients with DDP plus PTX or DOC resistant or refractory NSCLC were divided randomly into group NO (NVB plus OXA) and group GEMOX (GEM plus OXA).Thirty patients in group NO were treated with NVB 25mg/m2 at d1 and d8,and OXA 100mg/m2 at d1.Thirty patients in group GEMOX were treated with GEM 1000mg/m2 at d1 and d8,and OXA 100mg/m2 at d1.The drugs were given intravenously,and the treatments were repeated once every three weeks.Results In group NO,five patients achieved a partial response (PR),thirteen patients achieved a stable disease (SD),and twelve patients achieved a progress disease (PD).The overall response rate (ORR) was 16.7%,the disease control rate (DCR) was 60.0%,and the time to progression (TTP) was 3.3 months.In group GEMOX,6 patients achieved PR,11 patients achieved SD,13 patients achieved PD.The ORR was 20.0%,the DCR was 56.7%,and the TTP was 3.4 months.There was no significantly statistic difference between group NO and group GEMOX.The major adverse effects in both groups were neutropenia and peripheral sensory neuropathy,and there was no significantly statistic difference between the two groups either.Conclusions It is effective to treat DDP and PTX or DOC resistant or refractory advanced NSCLC by OXA combined with NVB or GEM.

Key words: Lung neoplasm/chemotherapy, Oxaliplatin, Vinorelbine, Gemcitabine, Paclitaxel